Eledon Pharmaceuticals
ELDN
48 hedge funds and large institutions have $70M invested in Eledon Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
9% more funds holding
Funds holding: 44 → 48 (+4)
23% less capital invested
Capital invested by funds: $91.2M → $70M (-$21.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$1.5M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$1.36M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.12M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$452K |
| 5 |
GOCM
Green Owl Capital Management
New York
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$3.17M |
| 2 |
AIC
AWM Investment Company
New York
|
-$1.47M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$664K |
| 4 |
PA
Perceptive Advisors
New York
|
-$368K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$351K |
ELDN Hedge Fund Activity: Q1 2015 in Review
48 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2015, worth a combined $70M — down 23% from $91.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ELDN positions and 5 closed out — a net gain of 4 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $1.5M. The largest seller was Redmile Group, exiting entirely with an estimated $3.17M sold.
- 48 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2015, up from 44 in Q4 2014.
- Funds reported $70M of Eledon Pharmaceuticals stock for Q1 2015, down 23% quarter-over-quarter.
- 9 funds opened new Eledon Pharmaceuticals positions in Q1 2015 and 5 closed out, a net change of +4 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2015 was Kingdon Capital Management, an estimated $1.5M added.
- The largest Eledon Pharmaceuticals seller in Q1 2015 was Redmile Group, an estimated $3.17M sold.
Based on aggregated 13F filings for Q1 2015.